Gland Pharma Share Price Jumps Over 5 Percent Today, Among Top Small Cap Gainers
- June 30, 2026
- Posted by: Ankit Jaiswal
- Category: News
Gland Pharma share price up over 5% to Rs 2,496 today, among top Nifty small cap gainers, extending recent momentum in the injectables space.
The Gland Pharma share price rose over 5 percent on Tuesday to trade around Rs 2,496, among the top small cap gainers on the Nifty, touching an intraday high of Rs 2,528.30. The stock has historically seen sharp single day moves around regulatory and earnings related news flow, and today’s gain extends a period of recovering investor interest in the stock.
Gland Pharma, a generic injectables focused pharmaceutical company with a global footprint across more than 60 countries, has a track record of strong stock reactions to US Food and Drug Administration approvals given the company’s heavy reliance on the US injectables market.
Click Here – Get Free Investment Predictions
Why the Gland Pharma Share Price Is Rallying Today
Gland Pharma has repeatedly seen its stock jump in the mid to high single digits on news of fresh USFDA approvals for its abbreviated new drug applications, a pattern consistent with today’s move. The company has also drawn renewed brokerage attention after Nomura upgraded the stock to Buy from Neutral, citing a more favourable risk reward profile following recent earnings revisions and the stock’s earlier correction, with the company expecting its base business to grow in double digits through FY27.
Gland Pharma’s most recent quarterly results showed a 28 percent jump in profit, supported by strong sales momentum in its key European and US markets, reinforcing the brokerage view that the earlier slump in the stock has likely bottomed out.
The table below summarises the key numbers behind today’s move.
| Metric | Value |
|---|---|
| NSE Symbol | GLAND |
| CMP (30 June 2026) | Rs 2,496 |
| Day Change | +5.2% |
| 52 Week High | Rs 2,131 |
| Markets Served | 60+ countries |
| Manufacturing Facilities | 7 in India |
Gland Pharma’s Injectables Business
Gland Pharma operates as a subsidiary of China’s Fosun Pharma and has built a strong track record of USFDA facility approvals without any major warning letters, a key differentiator in the generic injectables space. The company continues to expand its product registrations globally, with over 1,400 registrations across multiple markets supporting a diversified revenue base.
Track Gland Pharma on Univest Screener
What Should Investors Watch on Gland Pharma Now
Investors tracking the Gland Pharma share price should watch for further USFDA approvals, progress at the company’s French unit Cenexi, and quarterly updates on core business growth as management has guided for earnings to normalise through FY28.
Download the Univest iOS App or Univest Android App to track Gland Pharma’s live price and USFDA approval updates.
Conclusion
The Gland Pharma share price extended its recent recovery today, continuing a pattern of sharp gains the stock has historically shown around positive regulatory and earnings news flow. With Nomura recently turning constructive on the stock’s risk reward profile, investors will be watching upcoming quarters for confirmation of sustained double digit growth in the core business. Stock price movements are subject to market risk, so investors should consult a SEBI registered advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is the Gland Pharma share price up today?
Ans. The Gland Pharma share price rose over 5 percent today, extending a recent recovery; the stock has historically shown sharp gains around USFDA approval news and has drawn renewed brokerage interest after a recent Nomura upgrade.
What is the current Gland Pharma share price?
Ans. Gland Pharma was trading around Rs 2,496 on the NSE on 30 June 2026, up over 5 percent on the day.
Why has Nomura upgraded Gland Pharma?
Ans. Nomura upgraded Gland Pharma to Buy from Neutral, citing a more favourable risk reward profile following recent earnings revisions and the stock’s earlier correction, with the company guiding for double digit base business growth through FY27.
How did Gland Pharma perform in its most recent quarter?
Ans. Gland Pharma’s most recent quarterly results showed a 28 percent jump in profit, supported by strong sales momentum in its key European and US markets.
How many manufacturing facilities does Gland Pharma have?
Ans. Gland Pharma operates seven manufacturing units in India, comprising both finished formulation and API facilities.
Should investors buy Gland Pharma shares after this rally?
Ans. This article does not constitute investment advice. Investors should evaluate fundamentals and consult a SEBI registered advisor before making any investment decision.
What does Gland Pharma manufacture?
Ans. Gland Pharma is a generic injectables focused pharmaceutical company that manufactures finished formulations and active pharmaceutical ingredients for markets including the United States, Europe and India.
